The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research
Open accessAbstract
Scientific evidence collected over the past 4 decades suggests that a loss of cholinergic innervation in the cerebral cortex of patients with Alzheimer's disease is an early pathogenic event correlated with cognitive impairment. This evidence led to the formulation of the "Cholinergic Hypothesis of AD" and the development of cholinesterase inhibitor therapies. Although approved only as symptomatic therapies, recent studies suggest that long-term use of these drugs may also have disease-modifying benefits. A Cholinergic System Workgroup reassessed the role of the cholinergic system on AD pathogenesis in light of recent data, including neuroimaging data charting the progression of neurodegeneration in the cholinergic system and suggesting that cholinergic therapy may slow brain atrophy. Other pathways that contribute to cholinergic synaptic loss and their effect on cognitive impairment in AD were also reviewed. These studies indicate that the cholinergic system as one of several interacting systems failures that contribute to AD pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cholinesterase inhibitors can increase cholinergic activity by inhibiting acetylcholine degradation, which attenuates the cognitive decline of patients with dementia.425”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [425]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED AND REPLACED: Nerve growth factor metabolic dysfunction in Down’s syndrome brains
Iulita, M. F., Carmo, S. D., Ower, A. K., Fortress, A. M., Aguilar, L. F., Hanna, M., Wısnıewskı, T., Granholm, A., Buhusi, M. C., Busciglio, J. A., et al. (2014) · Brain · doi:10.1093/brain/awt372 · Cited by 96
Self-citationRetractedThe cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation
Coyle, J. T., Price, D. L., & DeLong, M. R. (1983) · Science · doi:10.1126/science.6338589 · Cited by 3,052
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198 · cited 1×
“…in a system regarded as fundamental for memory mechanisms contributes to age-associated memory losses, along with evidence of atrophy of that system in AD, became by extension the simplified “cholinergic hypothesis of Alzheimer’s disease” (32), and was understood as causative of the disease.”
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
Self-citationAlzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Self-citationHuman Memory and the Cholinergic System: A Relationship to Aging?
Drachman, D. A. (1974) · Archives of Neurology · doi:10.1001/archneur.1974.00490320001001 · Cited by 1,397
NEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
BOWEN, D. M., SMITH, C. B., WHITE, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,311
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196 · cited 1×
“For example, pharmacoepidemiology data suggest that long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) may protect against AD (74, 75); and at preclinical stages, NSAIDs may diminish significantly AD prevalence (42), while they are ineffective after its clinical presentation (43).”
Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer Type
Summers, W. K., Majovski, L. V., Marsh, G. M., Tachiki, K., & Kling, A. (1986) · New England Journal of Medicine · doi:10.1056/nejm198611133152001 · Cited by 1,163
THE ASCENDING CHOLINERGIC RETICULAR SYSTEM: NEOCORTICAL, OLFACTORY AND SUBCORTICAL PROJECTIONS
SHUTE, C. C. D., & LEWIS, P. R. (1967) · Brain · doi:10.1093/brain/90.3.497 · Cited by 1,118
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050
The cholinergic system in aging and neuronal degeneration
Schliebs, R., & Arendt, T. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.058 · Cited by 1,047
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892
The Cholinergic Synapse and the Site of Memory
Deutsch, J. A. (1972) · Advances in Behavioral Biology · doi:10.1007/978-1-4684-3060-8_11 · Cited by 739
The Cholinergic Synapse and the Site of Memory
Deutsch, J. A. (1971) · Science · doi:10.1126/science.174.4011.788 · Cited by 661
Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
Self-citationCholinergic system during the progression of Alzheimer’s disease: therapeutic implications
Mufson, E. J., Counts, S. E., Perez, S. E., & Ginsberg, S. D. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.11.1703 · Cited by 587
Cholinergic Markers in Elderly Patients With Early Signs of Alzheimer Disease
Davis, K. L. (1999) · JAMA · doi:10.1001/jama.281.15.1401 · Cited by 492
Intracerebroventricular Infusion of Nerve Growth Factor in Three Patients with Alzheimer’s Disease
Eriksdotter Jönhagen, M., Nordberg, A., Amberla, K., Bäckman, L., Ebendal, T., Meyerson, B., Olson, L., Seiger, Å., Shigeta, M., Theodorsson, E., et al. (1998) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017069 · Cited by 472
Alzheimer disease therapy—moving from amyloid-β to tau
Giacobini, E., & Gold, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.223 · Cited by 471
Self-citationThe Cholinergic Lesion of Alzheimer's Disease: Pivotal Factor or Side Show?
Mesulam, M. (2004) · Learning & Memory · doi:10.1101/lm.69204 · Cited by 467
Self-citationAcetylcholinesterase-rich projections from the basal forebrain of the rhesus monkey to neocortex
Mesulam, M.-M., & Van Hoesen, G. W. (1976) · Brain Research · doi:10.1016/0006-8993(76)90385-1 · Cited by 426
Self-citationThe Cholinergic Hypothesis: A Historical Overview, Current Perspective, and Future Directions
BARTUS, R. T., DEAN, R. L., PONTECORVO, M. J., & FLICKER, C. (1985) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1985.tb37600.x · Cited by 383
Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease
Mesulam, M. ‐. (2013) · Journal of Comparative Neurology · doi:10.1002/cne.23415 · Cited by 375
Self-citationCholinergic nucleus basalis tauopathy emerges early in the aging‐MCI‐AD continuum
Mesulam, M., Shaw, P., Mash, D., & Weintraub, S. (2004) · Annals of Neurology · doi:10.1002/ana.20100 · Cited by 374
Self-citationNordberg, A., & Winblad, B. (1986) · Neuroscience Letters · doi:10.1016/0304-3940(86)90629-4 · Cited by 361
Acetylcholine, Aging, and Alzheimer's Disease
Muir, J. L. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00431-5 · Cited by 360
Neurochemical Studies of Early-Onset Alzheimer's Disease: Possible Influence on Treatment
Francis, P. T., Palmer, A. M., Sims, N. R., Bowen, D. M., Davison, A. N., Esiri, M. M., Neary, D., Snowden, J. S., & Wilcock, G. K. (1985) · New England Journal of Medicine · doi:10.1056/nejm198507043130102 · Cited by 355
Bruno, M. A., & Cuello, A. C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510645103 · Cited by 344
Self-citationBasal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology
Schmitz, T. W., Nathan Spreng, R., Initiative, T. A. D. N., Weiner, M. W., Aisen, P., Petersen, R., Jack, C. R., Jagust, W., Trojanowki, J. Q., Toga, A. W., et al. (2016) · Nature Communications · doi:10.1038/ncomms13249 · Cited by 335
Self-citationShort-term memory in the rhesus monkey: Disruption from the anti-cholinergic scopolamine
Bartus, R. T., & Johnson, H. R. (1976) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(76)90286-0 · Cited by 328
Olson, L., Nordberg, A., von Holst, H., Bäckman, L., Ebendal, T., Alafuzoff, I., Amberla, K., Hartvig, P., Herlitz, A., Lilja, A., et al. (1992) · Journal of Neural Transmission - Parkinson's Disease and Dementia Section · doi:10.1007/bf02257624 · Cited by 323
Reduced incidence of AD with NSAID but not H2receptor antagonists: The Cache County Study
Zandi, P. P., Anthony, J. C., Hayden, K. M., Mehta, K., Mayer, L., & Breitner, J. C. S. (2002) · Neurology · doi:10.1212/wnl.59.6.880 · Cited by 316
NEURAL INPUTS INTO THE NUCLEUS BASALIS OF THE SUBSTANTIA INNOMINATA (Ch4) IN THE RHESUS MONKEY
MESULAM, M.-M., & MUFSON, E. J. (1984) · Brain · doi:10.1093/brain/107.1.253 · Cited by 316
Self-citationNerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease
Tuszynski, M. H., Yang, J. H., Barba, D., U, H.-S., Bakay, R. A. E., Pay, M. M., Masliah, E., Conner, J. M., Kobalka, P., Roy, S., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1807 · Cited by 287
Grothe, M., Heinsen, H., & Teipel, S. J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.06.019 · Cited by 281
Rogers, S. L., Doody, R. S., Pratt, R. D., & Ieni, J. R. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00067-5 · Cited by 265
Neurotrophic factor therapy for nervous system degenerative diseases
Hefti, F. (1994) · Journal of Neurobiology · doi:10.1002/neu.480251109 · Cited by 251
Measurement of basal forebrain atrophy in Alzheimer's disease using MRI
Teipel, S. J., Flatz, W. H., Heinsen, H., Bokde, A. L. W., Schoenberg, S. O., Stöckel, S., Dietrich, O., Reiser, M. F., Möller, H.-J., & Hampel, H. (2005) · Brain · doi:10.1093/brain/awh589 · Cited by 248
Self-citationSubregional Basal Forebrain Atrophy in Alzheimer's Disease: A Multicenter Study
Kilimann, I., Grothe, M., Heinsen, H., Alho, E. J. L., Grinberg, L., Amaro Jr., E., dos Santos, G. A. B., da Silva, R. E., Mitchell, A. J., Frisoni, G. B., et al. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132345 · Cited by 232
Self-citationGrothe, M., Zaborszky, L., Atienza, M., Gil-Neciga, E., Rodriguez-Romero, R., Teipel, S. J., Amunts, K., Suarez-Gonzalez, A., & Cantero, J. L. (2010) · Cerebral Cortex · doi:10.1093/cercor/bhp232 · Cited by 227
Giacobini, E., Spiegel, R., Enz, A., Veroff, A. E., & Cutler, N. R. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200089 · Cited by 222
Self-citationTargeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors
Castro, A., & Martinez, A. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778792985 · Cited by 207
Physostigmine and Recent Memory: Effects in Young and Aged Nonhuman Primates
Bartus, R. T. (1979) · Science · doi:10.1126/science.227061 · Cited by 207
Abnormalities of the nucleus basalis in Down's syndrome
Casanova, M. F., Walker, L. C., Whitehouse, P. J., & Price, D. L. (1985) · Annals of Neurology · doi:10.1002/ana.410180306 · Cited by 201
Drugs with anticholinergic properties: a current perspective on use and safety
Gerretsen, P., & Pollock, B. G. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.579899 · Cited by 194
Research update: Alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer's disease
Parri, H. R., Hernandez, C. M., & Dineley, K. T. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.039 · Cited by 187
Grothe, M., Heinsen, H., & Teipel, S. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.10.018 · Cited by 178
Neuropathological and biochemical observations on the noradrenergic system in Alzheimer's disease
Perry, E. K., Tomlinson, B. E., Blessed, G., Perry, R. H., Cross, A. J., & Crow, T. J. (1981) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(81)90106-4 · Cited by 171
Beach, T. G., Kuo, Y., Spiegel, K., Emmerling, M. R., Sue, L. I., Kokjohn, K., & Roher, A. E. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.4.308 · Cited by 168
Teipel, S. J., Meindl, T., Grinberg, L. T., Grothe, M. J., Cantero, J. L., Reiser, M. F., Möller, H., Heinsen, H., & Hampel, H. J. (2010) · Human Brain Mapping · doi:10.1002/hbm.21111 · Cited by 156
Self-citationFisher, A. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07507.x · Cited by 154
Amyloid β-Induced Nerve Growth Factor Dysmetabolism in Alzheimer Disease
Bruno, M. A., León, W., Fragoso, G., Mushynski, W. E., Almazán, G., & Cuello, A. C. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181aed9e6 · Cited by 154
Self-citationDonepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease
Dubois, B., Marie Chupin, A., Hampel, H. J., Lista, S., Cavedo, E., Croisile, B., Louis-Tisserand, G., Touchon, J., Bonafé, A., Ousset, P., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.10.003 · Cited by 149
Self-citationVellas, B., Carrillo, M. C., Sampaio, C., Brashear, H. R., Siemers, E., Hampel, H., Schneider, L. S., Weiner, M., Doody, R., Khachaturian, Z., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.03.007 · Cited by 147
Self-citationHampel, H., O’Bryant, S. E., Durrleman, S., Younesi, E., Rojkova, K., Escott-Price, V., Corvol, J.-C., Broich, K., Dubois, B., Lista, S., et al. (2017) · Climacteric · doi:10.1080/13697137.2017.1287866 · Cited by 147
Self-citationKadir, A., Almkvist, O., Wall, A. E., Långström, B., & Nordberg, A. K. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0447-7 · Cited by 146
Seiger, Å., Nordberg, A. K., von Holst, H., Bäckman, L., Ebendal, T., Alafuzoff, I. I., Amberla, K., Hartvig, P., Herlitz, A., Lilja, A., et al. (1993) · Behavioural Brain Research · doi:10.1016/0166-4328(93)90141-c · Cited by 139
Eyjolfsdottir, H., Eriksdotter, M., Linderoth, B., Lind, G., Juliusson, B., Kusk, P., Almkvist, O., Andreasen, N., Blennow, K., Ferreira, D., et al. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0195-9 · Cited by 137
Grothe, M. J., Heinsen, H., Amaro, E., Grinberg, L. T., & Teipel, S. J. (2015) · Cerebral Cortex · doi:10.1093/cercor/bhv062 · Cited by 130
Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease
Kerbler, G. M., Fripp, J., Rowe, C. C., Villemagne, V. L., Salvado, O., Rose, S., & Coulson, E. J. (2014) · NeuroImage Clinical · doi:10.1016/j.nicl.2014.11.015 · Cited by 127
PRECISION MEDICINE - THE GOLDEN GATE FOR DETECTION, TREATMENT AND PREVENTION OF ALZHEIMER’S DISEASE
Hampel, H. J., O’Bryant, S. E., Castrillo, J. I., Ritchie, C. W., Rojkova, K., Broich, K., Benda, N., Nisticò, R., Frank, R., Dubois, B., et al. (2016) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2016.112 · Cited by 121
Self-citationBasal forebrain atrophy is a presymptomatic marker for Alzheimer's disease
Hall, A. M., Moore, R. Y., López, O. L., Kuller, L. H., & Becker, J. T. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.04.005 · Cited by 120
Cavedo, E., Grothe, M. J., Olivier Colliot, A., Lista, S., Marie Chupin, A., Dormont, D., Houot, M., Lehéricy, S., Teipel, S. J., Dubois, B., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09780-3 · Cited by 119
Self-citationChronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease
Doody, R. S., Dunn, J. K., Clark, C. M., Farlow, M., Foster, N. L., Liao, T., Gonzales, N., Lai, E., & Massman, P. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051272 · Cited by 118
Self-citationBasal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects
Grothe, M. J., Ewers, M., Krause, B. J., Heinsen, H., & Teipel, S. J. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.09.011 · Cited by 110
Long-term effects of rivastigmine in moderately severe Alzheimer's disease
Doraiswamy, P. M., Krishnan, K., Anand, R., Sohn, H., Danyluk, J., Hartman, R. D., & Veach, J. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00326-8 · Cited by 108
Neuroinflammation in the Aging Down Syndrome Brain; Lessons from Alzheimer's Disease
Wilcock, D. M. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/170276 · Cited by 104
Impact of the NGF Maturation and Degradation Pathway on the Cortical Cholinergic System Phenotype
Allard, S., León, W., Pakavathkumar, P., Bruno, M. A., Ribeiro‐da‐Silva, A., & Cuello, A. C. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1144-11.2012 · Cited by 102
Self-citationIulita, M. F., Ower, A., Barone, C., Pentz, R., Gubert, P., Romano, C., Cantarella, R. A., Elia, F., Buono, S., Recupero, M., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.05.001 · Cited by 99
Self-citationChapter 34 The cholinergic system in Alzheimer disease
Giacobini, E. (1990) · Progress in brain research · doi:10.1016/s0079-6123(08)60916-4 · Cited by 98
Self-citationEffectiveness of antidementia drugs in delaying Alzheimer's disease progression
Rountree, S. D., Atri, A., Lopez, O. L., & Doody, R. S. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.01.002 · Cited by 97
Donepezil-induced REM sleep augmentation enhances memory performance in elderly, healthy persons
Schredl, M., Weber, B., Leins, M.-L., & Heuser, I. (2001) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00206-0 · Cited by 96
Potter, P. E., Rauschkolb, P. K., Pandya, Y., Sue, L. I., Sabbagh, M. N., Walker, D. G., & Beach, T. G. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0831-1 · Cited by 94
Aphasic variant of Alzheimer disease: Clinical, anatomic, and genetic features
Rogalski, E. J., Sridhar, J., Rader, B. M., Martersteck, A., Chen, K., Cobia, D. J., Thompson, C. K., Weıntraub, S., Bigio, E. H., & Mesulam, M. M. (2016) · Neurology · doi:10.1212/wnl.0000000000003165 · Cited by 94
Self-citationAmnesic properties of scopolamine and brain acetylcholine in the rat
Pazzagli, A., & Pepeu, G. (1965) · International Journal of Neuropharmacology · doi:10.1016/0028-3908(65)90025-0 · Cited by 91
Acetylcholine, aging and Alzheimer's disease
Corkin, S. (1981) · Trends in Neurosciences · doi:10.1016/0166-2236(81)90090-4 · Cited by 90
Deardorff, W. J., Shobassy, A., & Grossberg, G. T. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.995639 · Cited by 85
AF710B, a Novel M1/σ1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer's Disease
Fisher, A., Борисович, Б. И., Wu, L., Ryskamp, D. A., Bar-Ner, N., Natan, N., Brandeis, R., Elkon, H., Nahum, V., Gershonov, E., et al. (2015) · Neurodegenerative Diseases · doi:10.1159/000440864 · Cited by 82
Beach, T. G., Honer, W. G., & Hughes, L. H. (1997) · Acta Neuropathologica · doi:10.1007/s004010050595 · Cited by 79
Lim, Y. Y., Maruff, P. T., Schindler, R. J., Ott, B. R., Salloway, S., Yoo, D. C., Noto, R. B., Santos, C. Y., & Snyder, P. J. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.07.009 · Cited by 78
Self-citationFredrickson, A., Snyder, P. J., Cromer, J., Thomas, E. H. X., Lewis, M., & Maruff, P. T. (2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.942 · Cited by 71
Self-citationAlmkvist, O., Darreh‐Shori, T., Stefanova, E. D., Spiegel, R., & Nordberg, A. K. (2004) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00757.x · Cited by 58
Thomas, E. H. X., Snyder, P. J., Pietrzak, R. H., Jackson, C. E., Bednar, M. M., & Maruff, P. T. (2008) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2008.04.010 · Cited by 53
Self-citationCavedo, E., for the Hippocampus Study Group, Dubois, B., Olivier Colliot, A., Lista, S., Croisile, B., Louis-Tisserand, G., Touchon, J., Bonafé, A., Ousset, P., et al. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10413 · Cited by 53
Self-citationFarlow, M. R., Lilly, M. L., & for the ENA713 B352 Study Group (2005) · BMC Geriatrics · doi:10.1186/1471-2318-5-3 · Cited by 50
Self-citationMethodological Issues in Primary Prevention Trials for Neurodegenerative Dementia
Andrieu, S., Coley, N., Aisen, P. S. S., Carrillo, M. C., DeKosky, S. T., Durga, J., Fillit, H. M., Frisoni, G. B., Froelich, L., Gauthier, S. G., et al. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0971 · Cited by 49
Self-citationSnapShot: Pathobiology of Alzheimer's Disease
Selkoe, D. J. (2013) · Cell · doi:10.1016/j.cell.2013.07.003 · Cited by 46
Vellas, B. J., Hampel, H. J., Bugat, M.-È. R., Grundman, M., Andrieu, S., Abushakra, S. R., Bateman, R. J., Berman, R., Black, R. S., Carrillo, M. C., et al. (2012) · The journal of nutrition health & aging · doi:10.1007/s12603-012-0044-x · Cited by 45
Self-citationDifferential impairment of delayed matching in monkeys by scopolamine and scopolamine methylbromide
Bohdaneck�, Z., Jarvik, M. E., & Carley, J. L. (1967) · Psychopharmacology · doi:10.1007/bf00404606 · Cited by 45
Chapter 33 Effects of trophic factors on the CNS cholinergic phenotype
Cuello, A. C. (1996) · Progress in brain research · doi:10.1016/s0079-6123(08)62117-2 · Cited by 43
Self-citationCholinergic Aspects of Aging and Alzheimer's Disease
Mesulam, M. M. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.02.025 · Cited by 40
Self-citationCircadian Cholinergic Rhythms: Implications for Cholinesterase Inhibitor Therapy
Davis, B. M., & Sadik, K. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000090630 · Cited by 38
Snyder, P. J., Lim, Y. Y., Schindler, R. J., Ott, B. R., Salloway, S., Daiello, L. A., Getter, C., Gordon, C. M., & Maruff, P. T. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.01.009 · Cited by 37
Self-citationOptimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease
Mohs, R. C., Kawas, C. H., & Carrillo, M. C. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.04.003 · Cited by 32
Prevent Alzheimer's disease by 2020: A national strategic goal
Khachaturian, Z. S., & Khachaturian, A. S. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.01.022 · Cited by 32
Self-citationPapp, K. V., Snyder, P. J., Maruff, P. T., Bartkowiak, J., & Pietrzak, R. H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021688 · Cited by 32
Self-citationThe Special Topics Section of Alzheimer's & Dementia
Khachaturian, Z. S., Mesulam, M. M., Khachaturian, A. S., & Mohs, R. C. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.10.002 · Cited by 28
Self-citationGlobal issues in drug development for Alzheimer's disease
Doody, R. S., Cole, P. E., Miller, D. S., Siemers, E., Black, R. S., Feldman, H., Schindler, R. J., Graham, S. M., Heath, T., Khachaturian, A. S., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.01.001 · Cited by 15
Self-citationNew and different approaches needed for the design and execution of Alzheimer's clinical trials
Carrillo, M. C., & Vellas, B. J. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.03.008 · Cited by 6
Optimal use of cholinergic drugs in Alzheimer’s disease
Gauthier, S. G., Herrmann, N., & Rosa‐Neto, P. (2018) · Brain · doi:10.1093/brain/awy204 · Cited by 5
Cited by
Lamptey, R. N. L., Chaulagain, B., Trivedi, R., Gothwal, A., Layek, B., & Singh, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031851 · Cited by 900
Walczak-Nowicka, Ł. J., & Herbet, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179290 · Cited by 335
Fernández-Calle, R., Konings, S. C., Frontiñán-Rubio, J., García-Revilla, J., Camprubí-Ferrer, L., Svensson, M., Martinson, I., Boza-Serrano, A., Venero, J. L., Nielsen, H. M., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00566-4 · Cited by 278
Albertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179
The Potential Role of Cytokines and Growth Factors in the Pathogenesis of Alzheimer’s Disease
Ogunmokun, G., Dewanjee, S., Chakraborty, P., Valupadas, C., Chaudhary, A., Kolli, V., Anand, U., Vallamkondu, J., Goel, P., Paluru, H. P. R., et al. (2021) · Cells · doi:10.3390/cells10102790 · Cited by 85
Metadata
- Authors
- Hampel, H., Mesulam, M.-M., Cuello, A. C., Khachaturian, A. S., Vergallo, A., Farlow, M. R., Snyder, P. J., Giacobini, E., & Khachaturian, Z. S.
- Venue
- The Journal of Prevention of Alzheimer's Disease
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 6
- Issue
- 1
- Pages
- 2-15
- ISSN
- 2274-5807 (ISSN-L)
- OpenAlex
- W2903299905
- Cited by
- 369
- References
- 107
- FWCI
- 18.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.